Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.monoclonal_antibodyPhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 59/ 100
Competitive context
1205 Active assets in the Non-Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →